Bezafibrate reduces blood glucose in type 2 diabetes mellitus
References (20)
- et al.
The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation
Biochim Biophys Acta
(1996) - et al.
The peroxisome proliferator—activated receptor α (PPAR-α) regulates the plasma thiobarbituric acid—reactive substance (TBARS) levels
Biochem Biophys Res Commun
(1997) - et al.
Effect of bezafibrate on lipoprotein secretion by cultured human hepatocytes
Atherosclerosis
(1987) - et al.
Relationship between plasma free fatty acid concentration, endogenous glucose production and fasting hyperglycemia in normal and non—insulin-dependent diabetic individuals
Metabolism
(1987) - et al.
Apolipoproteins in diabetes mellitus
- et al.
Prospective analysis of the insulin-resistance (syndrome X)
Diabetes
(1992) - et al.
Contribution of intraabdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity
Metabolism
(1987) - et al.
Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease
Diabetes Care
(1991) - et al.
Tumor necrosis factor alpha: A key component of the obesity-diabetes link
Diabetes
(1994) - et al.
Tumor necrosis factor α acutely inhibits insulin signaling in human adipocytes
Diabetes
(1998)
Cited by (54)
Sweroside ameliorates NAFLD in high-fat diet induced obese mice through the regulation of lipid metabolism and inflammatory response
2020, Journal of EthnopharmacologyCitation Excerpt :However, PPAR-α agonist fibrates are used to decrease plasma triglycerides and increase high-density lipoprotein cholesterol in clinical (Tenenbaum et al., 2005). Moreover, fibrates also modulates lipid metabolism and improves insulin resistance in obese mice (Ogawa et al., 2000). In addition, another PPAR-α agonist Wy-14643 has been proved to lower hepatic TG and improves insulin sensitivity in mice (Ye et al., 2001).
Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes
2016, Pharmacological ResearchCitation Excerpt :Synthetic agonists of PPARα, such as fibrates, are clinically used to lower plasma triglycerides and increase high-density lipoprotein cholesterol [14]. In addition to the beneficial lipid modulation, fibrates improve insulin sensitivity in animal models of obesity [15]. The PPARγ isoform is also highly expressed in various cell types and organs, including adipocytes, muscle cells, the liver and the kidney, and is recognized as a master regulator of glucose homeostasis.
Short-term selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key β-cell factors under diabetic conditions
2015, Biochemical and Biophysical Research CommunicationsCitation Excerpt :It is expected that a longer period of treatment than one week would lead to greater improvement of critical GSIS-associated genes, such as Gck and Kcnj11, and better β-cell function. However, we chose a shorter period of treatment because long-term administration of SGLT2 inhibitors or fibrates were reported to relieve hyperlipidemia [23,24] or hyperglycemia [25,26], respectively, and we thought that these would make it difficult to evaluate the individual effects of alleviating glucotoxicity or lipotoxicity on β-cell gene expression and function. As a result, our data clearly showed that selective reduction of glucotoxicity for one week resulted in beneficial effects on the expression of key β-cell molecules and initiated improvements of β-cell function and mass, although further reduction of glucotoxicity or lipotoxicity may be required for a substantial restoration of β-cell function.
Activation of peroxisome proliferator-activated receptor-α enhances fatty acid oxidation in human adipocytes
2011, Biochemical and Biophysical Research CommunicationsAtorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia
2011, Pharmacological ReportsCitation Excerpt :Numerous multicenter randomized trials and smaller studies have estimated the effects of hypolipi-demic drugs on the serum concentrations of adipokines.[31] The treatment with bezafibrate [32] or the administration of fenofibrate [9] reduced the leptin levels in dyslipidemic patients who had type 2 diabetes mellitus. The bezafibrate-treated subjects who were enrolled in the Bezafibrate Infarction Prevention study displayed higher adiponectin levels than the placebo-treated patients [18].